Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Pat

Tiziana Announces the FDA Has Allowed Treatment for a Secondary

Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody,

Under an Individual Patient Expanded Access Program

New York/London, 30 March 2021 -

Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company

focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug Administration

(FDA) has allowed evaluation of nasal administration with Foralumab, a fully human anti-CD3 monoclonal antibody, in a secondary

progressive multiple sclerosis (SPMS) patient at the Brigham and Women's Hospital (BWH), Harvard University, Boston, MA.

This patient will be treated under an Individual Patient Expanded Access IND. This is the first time a nasally administered antibody

will be administered to a patient with SPMS. The treatment is planned to start in the second quarter of 2021, and will continue

for six months. Investigators at BWH will follow this patient with detailed routine safety, neurological, imaging and PET studies

to evaluate microglial imaging. Modification of immunological and neurodegenerative markers is part of standard investigations

that will be conducted at the BWH.

Previously, Tiziana completed

a Phase 1 trial of a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) once a day dosing for 5 consecutive

days with nasally administered Foralumab in healthy subjects. The treatment was well-tolerated with no drug-related safety issues

reported at any doses up to 250 mg of the doses. Nasal foralumab was developed by Professor Howard Weiner at BWH.

Weiner commented, "Nasal anti-CD3

is an exciting, novel approach that has the ability to provide a safe treatment for a form of MS that has no effective treatment.

We are pleased that the FDA has allowed us to treat a patient with SPMS who needs a better treatment option than is currently available."

Dr. Tanuja Chitnis, Professor of Neurology

at Harvard Medical School and senior neurologist at the BWH, adds, "New treatments for progressive MS are urgently needed.

Nasal Foralumab could revolutionize treatment for this disabling form of disease."

The company had previously

reported positive data from the Clinical Study of Nasal Administration with Foralumab in COVID-19 patients in Brazil. Nasally administered

Foralumab at 100 mg/day for consecutive 10 days treatment was found to be well-tolerated, and there were no apparent severe adverse

events. The clinical data suggested that the treatment provided significant reduction of lung inflammation.

Foralumab (formerly NI-0401), the only entirely human anti-CD3

mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases in the classic

side effects of cytokine release syndrome and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID

IL2 c-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses

of the T cells, enhances regulatory T-cells (Tregs) and thus provides therapeutic benefit in treating inflammatory and autoimmune

diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017).

Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune

and inflammatory diseases in a safe manner by the induction of Tregs.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed

(NASDAQ: TLSA, UK LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human

diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase

2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive multiple

sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world.

This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's

Disease, multiple sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and

rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin

6 receptor ("IL6R") mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for

treatment of COVID-19 patients.

For further enquiries: